Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study on the Safety and Efficacy of Atorvastatin in Combination With Axitinib and Toripalimab for Advanced Renal Cell Carcinoma Guided by Drug Sensitivity Testing Using Patient-Derived Tumor Cell Models

NCT07630363 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT07630363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07630363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study on the Safety and Efficacy of Atorvastatin in Combination With Axitinib and Toripalimab for Advanced Renal Cell Carcinoma Guided by Drug Sensitivity Testing Using Patient-Derived Tumor Cell Models
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 14, 2026
Completion date
April 1, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma (rcc), atorvastatin, ptc, targeted therapy combined with immunotherapy